Ensysce Biosciences, Inc._
Stock Overview
About
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Company Details
Frequently Asked Questions
What does Ensysce Biosciences, Inc. do?
Ensysce Biosciences, Inc. is a company in the biotechnology industry industry. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products
When was Ensysce Biosciences, Inc. founded?
Ensysce Biosciences, Inc. was founded in , making it 23 years old.
Where is Ensysce Biosciences, Inc. headquartered?
Ensysce Biosciences, Inc. is headquartered in La Jolla, CA, United States.
How many employees does Ensysce Biosciences, Inc. have?
Ensysce Biosciences, Inc. employs approximately 7 people worldwide.
Is Ensysce Biosciences, Inc. publicly traded?
Yes, Ensysce Biosciences, Inc. is a publicly traded company with the stock ticker symbol ENSC.
